Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies.

Israel Franco,Piet Hoebeke,Małgorzata Baka-Ostrowska,David Bolong, Leon N Davies, Ellen Dahler,Robert Snijder,Otto Stroosma, Frank Verheggen,Donald Newgreen,Brigitte Bosman,Johan Vande Walle

Journal of Pediatric Urology（2020）

引用 12|浏览13

暂无评分

摘要

Solifenacin was effective and well tolerated in pediatric patients with NDO, aged 6 months-<18 years, suggesting that it is a viable alternative to oxybutynin, the current standard of care. STUDIES ARE REGISTERED AT CLINICALTRIALS.GOV: NCT01981954 and NCT01565694.

查看译文

关键词

Children,Adolescents,Neurogenic urinary bladder,Solifenacin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要